PRN.TO - Profound Medical Corp.

Toronto - Toronto Delayed Price. Currency in CAD
21.30
+0.91 (+4.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close20.39
Open21.01
Bid20.90 x 0
Ask21.36 x 0
Day's Range20.00 - 21.49
52 Week Range7.30 - 27.45
Volume33,752
Avg. Volume58,943
Market Cap410.131M
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-1.73
Earnings DateAug 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.37
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Profound Medical to Release Second Quarter 2020 Financial Results on August 6 – Conference Call to Follow

      TORONTO, July 22, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its second quarter 2020 financial results after market close on Thursday, August 6, 2020. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.Second Quarter 2020 Results Conference Call Details:     Date: Thursday, August 6, 2020     Time: 4:30 p.m. ET     Live Call: 1-844-407-9500 (Canada and the United States)   1-862-298-0850 (International)     Replay: 1-919-882-2331 Replay ID: 35945 The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section. About Profound Medical Corp.Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.Forward-Looking StatementsThis release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate disease, uterine fibroids and palliative pain treatment. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.  Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.For further information, please contact:Stephen Kilmer Investor Relations skilmer@profoundmedical.com T: 647.872.4849

    • GlobeNewswire

      Profound Medical Announces Closing of Offering

      TORONTO, July 21, 2020 -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced.

    • GlobeNewswire

      Profound Medical Announces Pricing of Offering of Common Shares

      TORONTO, July 15, 2020 -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering.

    • GlobeNewswire

      Profound Medical Announces Proposed Offering of Common Shares

      TORONTO, July 15, 2020 -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectus.

    • Hedge Funds Are Nibbling On Profound Medical Corp. (PROF)
      Insider Monkey

      Hedge Funds Are Nibbling On Profound Medical Corp. (PROF)

      In this article we will check out the progression of hedge fund sentiment towards Profound Medical Corp. (NASDAQ:PROF) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

    • GlobeNewswire

      Profound Medical Annual and Special Meeting of Shareholders Voting Results

      Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). All of the matters put forward before the shareholders, as set out in the Company’s management information circular dated April 13, 2020 (the “Information Circular”), were approved by the requisite majority of votes cast at the Meeting. At the meeting, the shareholders of the Company elected all seven nominees for the board of directors (the “Board”).

    • Analysts Are Upgrading Profound Medical Corp. (TSE:PRN) After Its Latest Results
      Simply Wall St.

      Analysts Are Upgrading Profound Medical Corp. (TSE:PRN) After Its Latest Results

      A week ago, Profound Medical Corp. (TSE:PRN) came out with a strong set of first-quarter numbers that could...

    • GlobeNewswire

      Profound Medical Announces First Quarter 2020 Financial Results

      TORONTO, May 07, 2020 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which.

    • GlobeNewswire

      Profound Medical to Release First Quarter 2020 Financial Results on May 7 – Conference Call to Follow

      Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its first quarter 2020 financial results after market close on Thursday, May 7, 2020. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

    • Profound Medical Corp.'s (TSE:PRN) Profit Outlook
      Simply Wall St.

      Profound Medical Corp.'s (TSE:PRN) Profit Outlook

      Profound Medical Corp.'s (TSE:PRN): Profound Medical Corp. operates as a medical technology company focuses on magnetic...

    • GlobeNewswire

      Profound Medical Announces Fourth Quarter and Full Year 2019 Financial Results

      TORONTO, March 03, 2020 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable,.

    • GlobeNewswire

      Profound Medical Participate in March Investor Healthcare Conferences

      Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will participate in two investor conferences in March. Cowen and Company's 40th Annual Health Care Conference: Profound is scheduled to present on March 4, 2020 at 10:40 a.m. Eastern Time at the Boston Marriott Copley Place hotel. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

    • GlobeNewswire

      Profound Medical to Release Fourth Quarter and Full Year 2019 Financial Results on March 3 – Conference Call to Follow

      Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its fourth quarter and full year 2019 financial results after market close on Tuesday, March 3, 2020. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

    • GlobeNewswire

      Profound Medical Retires Bank Debt Ahead of Schedule

      Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced that it has retired its $12.5 million in principal amount loan with Canadian Imperial Bank of Commerce (“CIBC”), maturing on July 29, 2022. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities.

    • CNW Group

      IIROC Trade Resumption - PRN

      IIROC Trade Resumption - PRN

    • CNW Group

      IIROC Trading Halt - PRN

      IIROC Trading Halt - PRN

    • Announcing: Profound Medical (TSE:PRN) Stock Increased An Energizing 101% In The Last Year
      Simply Wall St.

      Announcing: Profound Medical (TSE:PRN) Stock Increased An Energizing 101% In The Last Year

      When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find...

    • GlobeNewswire

      Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenues & Provides TULSA-PRO® U.S. Commercialization Update

      Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2019, and provided an update on the early progress it is making with the commercialization of TULSA-PRO® in the United States. Profound anticipates total revenues for the fourth quarter of 2019 to be approximately $2.7 million, representing growth of 59% year-over-year and 296% sequentially over the previous quarter.

    • GlobeNewswire

      Profound Medical and RadNet Sign the First-Ever U.S. Multi-Center Commercial Agreement for TULSA-PRO®

      Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced the signing of its first-ever U.S. multi-site imaging center agreement for TULSA-PRO® with RadNet, Inc. (RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 340 owned and/or operated outpatient imaging centers. TULSA-PRO® is a transurethral prostate tissue ablation system that combines real-time MRI with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.

    • Is Profound Medical Corp.'s (TSE:PRN) CEO Paid Enough Relative To Peers?
      Simply Wall St.

      Is Profound Medical Corp.'s (TSE:PRN) CEO Paid Enough Relative To Peers?

      In 2016 Arun Menawat was appointed CEO of Profound Medical Corp. (TSE:PRN). This report will, first, examine the CEO...

    • GlobeNewswire

      Profound Medical to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

      Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will present an update on the Company’s business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 1:00 p.m. Eastern Time. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section. Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

    • GlobeNewswire

      Profound Medical Announces Health Canada Approval of TULSA-PRO®

      Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced Health Canada approval of the TULSA-PRO® system for the ablation of low to intermediate risk organ-confined prostate cancer. TULSA-PRO® is a transurethral prostate tissue ablation system that combines real-time Magnetic Resonance Imaging (“MRI”) with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.

    • Who Has Been Buying Profound Medical Corp. (TSE:PRN) Shares?
      Simply Wall St.

      Who Has Been Buying Profound Medical Corp. (TSE:PRN) Shares?

      It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

    • GlobeNewswire

      Profound Medical Announces Third Quarter 2019 Financial Results

      TORONTO, Nov. 07, 2019 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which.

    • Profound Medical Corp. Opens the Market
      CNW Group

      Profound Medical Corp. Opens the Market

      Profound Medical Corp. Opens the Market